JP2011509074A - 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス - Google Patents

活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス Download PDF

Info

Publication number
JP2011509074A
JP2011509074A JP2010538832A JP2010538832A JP2011509074A JP 2011509074 A JP2011509074 A JP 2011509074A JP 2010538832 A JP2010538832 A JP 2010538832A JP 2010538832 A JP2010538832 A JP 2010538832A JP 2011509074 A JP2011509074 A JP 2011509074A
Authority
JP
Japan
Prior art keywords
formula
compound
cells
group
transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010538832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509074A5 (https=
Inventor
ゼルファティ，オリビエ
ムタール，ステファヌ
Original Assignee
オズ ビオスイヤーンス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オズ ビオスイヤーンス filed Critical オズ ビオスイヤーンス
Publication of JP2011509074A publication Critical patent/JP2011509074A/ja
Publication of JP2011509074A5 publication Critical patent/JP2011509074A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010538832A 2007-12-19 2008-12-16 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス Pending JP2011509074A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0708861A FR2925491B1 (fr) 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
PCT/FR2008/001755 WO2009106713A2 (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Publications (2)

Publication Number Publication Date
JP2011509074A true JP2011509074A (ja) 2011-03-24
JP2011509074A5 JP2011509074A5 (https=) 2012-01-19

Family

ID=39731919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538832A Pending JP2011509074A (ja) 2007-12-19 2008-12-16 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス

Country Status (6)

Country Link
US (1) US9107931B2 (https=)
EP (1) EP2285772B1 (https=)
JP (1) JP2011509074A (https=)
CA (1) CA2708988C (https=)
FR (1) FR2925491B1 (https=)
WO (1) WO2009106713A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121942A1 (ja) * 2015-01-30 2016-08-04 日油株式会社 カチオン性脂質
JP2019532069A (ja) * 2016-10-13 2019-11-07 カーノット， エルエルシー Ｎ−アシルエタノールアミド誘導体およびその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851280C (en) 2011-10-11 2021-05-18 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
EP2831034B1 (en) 2012-03-28 2019-07-31 University of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine-macrocyclic conjugates
CA2868463C (en) 2012-03-28 2021-01-19 University Of Central Florida Research Foundation, Inc. Polyamine transport selective therapeutic agents with enhanced stability
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US8853278B1 (en) 2013-05-22 2014-10-07 Curza Global, Llc Compositions comprising a biocidal polyamine
US9439433B2 (en) 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
US20160110406A1 (en) * 2014-10-16 2016-04-21 Microsoft Technology Licensing, Llc Validation of data across multiple data stores
EP3218012A1 (en) 2014-11-10 2017-09-20 ethris GmbH Induction of osteogenesis by delivering bmp encoding rna
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CA3058813A1 (en) 2017-04-05 2018-10-11 University Of Utah Research Foundation Compositions and methods comprising a triaryl polyamine
CN118949075A (zh) 2019-02-14 2024-11-15 埃泽瑞斯公司 纤毛疾病的治疗
EP4553084A3 (en) 2020-11-04 2025-11-26 Ethris GmbH Use of ifn-lambda mrna for treating viral infections
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency
EP4480943A1 (en) * 2023-06-22 2024-12-25 Oz Biosciences New class of lipids for delivering active ingredients into cells
IT202300015291A1 (it) 2023-07-20 2025-01-20 Fond Riccardo Terzi E Silvio Albini Sistema di rilascio comprendente nanoparticelle lipidiche o polimeriche comprendenti ormoni tiroidei
WO2025097659A1 (en) * 2023-11-08 2025-05-15 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025209467A1 (en) * 2024-04-01 2025-10-09 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08239398A (ja) * 1995-03-03 1996-09-17 Sogo Yatsukou Kk 水不溶性、自己支持性透明ｄｎａ・脂質複合体フィルムおよびその製造方法
JPH09173067A (ja) * 1995-11-22 1997-07-08 F Hoffmann La Roche Ag 細胞のトランスフェクション
JPH09202799A (ja) * 1996-01-17 1997-08-05 F Hoffmann La Roche Ag トランスフェクション能を有する分子
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
JPH10510813A (ja) * 1994-12-09 1998-10-20 ジェンザイム・コーポレイション 治療分子の細胞内送達のためのカチオン性両親媒性化合物およびプラスミド
JP2000515138A (ja) * 1996-07-15 2000-11-14 ジエンザイム コーポレイション 治療用分子の細胞内送達のためのカチオン性両親媒性組成物
JP2000516209A (ja) * 1996-07-12 2000-12-05 ジエンザイム コーポレイション カチオン性両親媒性物質／ｄｎａ複合体
JP2004508364A (ja) * 2000-09-05 2004-03-18 ジヤンセル・エス・アー 酸感受性化合物、該化合物の製造および使用
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
WO2006118327A1 (ja) * 2005-04-27 2006-11-09 Oxygenix Co Ltd カチオン性アミノ酸型脂質

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1351368A (fr) * 1960-12-05 1964-02-07 Merck & Co Inc Composés d'isocyanates organiques et leur procédé de fabrication
CH448122A (de) * 1963-10-14 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung von Estern
JPS6039716B2 (ja) * 1982-02-02 1985-09-07 ライオン株式会社 カチオン性界面活性剤組成物
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
WO1987002367A2 (en) * 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
EP0320976A1 (en) * 1987-12-18 1989-06-21 Ajinomoto Co., Inc. Arginine derivatives and cosmetic compositions comprising the same
AU666416B2 (en) * 1993-01-29 1996-02-08 Tanabe Seiyaku Co., Ltd. Ellipticine derivative and process for preparing the same
GB9326518D0 (en) * 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds
EP0784984B1 (en) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Transfection competent molecules
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
US20060148734A1 (en) * 2002-03-27 2006-07-06 Patrick Camilleri Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
WO2007079394A2 (en) * 2005-12-30 2007-07-12 Revance Therapeutics, Inc. Arginine heteromers for topical administration

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
JPH10510813A (ja) * 1994-12-09 1998-10-20 ジェンザイム・コーポレイション 治療分子の細胞内送達のためのカチオン性両親媒性化合物およびプラスミド
JPH08239398A (ja) * 1995-03-03 1996-09-17 Sogo Yatsukou Kk 水不溶性、自己支持性透明ｄｎａ・脂質複合体フィルムおよびその製造方法
JPH09173067A (ja) * 1995-11-22 1997-07-08 F Hoffmann La Roche Ag 細胞のトランスフェクション
JPH09202799A (ja) * 1996-01-17 1997-08-05 F Hoffmann La Roche Ag トランスフェクション能を有する分子
JP2000516209A (ja) * 1996-07-12 2000-12-05 ジエンザイム コーポレイション カチオン性両親媒性物質／ｄｎａ複合体
JP2000515138A (ja) * 1996-07-15 2000-11-14 ジエンザイム コーポレイション 治療用分子の細胞内送達のためのカチオン性両親媒性組成物
JP2004508364A (ja) * 2000-09-05 2004-03-18 ジヤンセル・エス・アー 酸感受性化合物、該化合物の製造および使用
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
WO2006118327A1 (ja) * 2005-04-27 2006-11-09 Oxygenix Co Ltd カチオン性アミノ酸型脂質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALAVOSKLISH BIKRAM, ET AL., MACROMOLECULES, vol. 37, no. 5, JPN6015000109, 2 November 2004 (2004-11-02), pages 1903 - 1916, ISSN: 0002979055 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121942A1 (ja) * 2015-01-30 2016-08-04 日油株式会社 カチオン性脂質
JPWO2016121942A1 (ja) * 2015-01-30 2017-11-24 日油株式会社 カチオン性脂質
JP2019532069A (ja) * 2016-10-13 2019-11-07 カーノット， エルエルシー Ｎ−アシルエタノールアミド誘導体およびその使用
JP7041673B2 (ja) 2016-10-13 2022-03-24 カーノット， エルエルシー Ｎ－アシルエタノールアミド誘導体およびその使用

Also Published As

Publication number Publication date
WO2009106713A2 (fr) 2009-09-03
WO2009106713A3 (fr) 2009-11-26
FR2925491A1 (fr) 2009-06-26
FR2925491B1 (fr) 2010-09-03
CA2708988A1 (fr) 2009-09-03
US20120015865A1 (en) 2012-01-19
CA2708988C (fr) 2017-03-28
US9107931B2 (en) 2015-08-18
EP2285772B1 (fr) 2022-07-13
EP2285772A2 (fr) 2011-02-23

Similar Documents

Publication Publication Date Title
US9107931B2 (en) Class of cationic lipids for transporting active agents into cells
ES2208936T3 (es) Complejos de lipidos cationicos-acidos nucleicos.
JP5796113B2 (ja) トランスフェクションエンハンサー要素を含む脂質および脂質集合体
Zhang et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery
JP4467084B2 (ja) 核酸を細胞に導入するための化合物、その製法及びその使用
Damen et al. Transfection by cationic gemini lipids and surfactants
US20140187614A1 (en) Amino lipids, their synthesis and uses thereof
JP2024519715A (ja) ペプチド－脂質コンジュゲートを含む脂質組成物
US20120021044A1 (en) Novel Cationic Lipid, A Preparation Method of the Same and A Delivery System Comprising the Same
Dharmalingam et al. Green transfection: Cationic lipid nanocarrier system derivatized from vegetable fat, palmstearin enhances nucleic acid transfections
Maiti et al. Transfection efficiencies of α-tocopherylated cationic gemini lipids with hydroxyethyl bearing headgroups under high serum conditions
Tseng et al. Liposome-based gene therapy
CN102665761A (zh) 活性产生递送分子
Radchatawedchakoon et al. The effect of polar headgroups and spacer length on the DNA transfection of cholesterol-based cationic lipids
US8338643B2 (en) Reagent for introduction of protein or gene
JP2024518379A (ja) ペプチド－脂質コンジュゲート
EP4620948A1 (en) Lipid compound and composition for delivery of active substance
JP6826014B2 (ja) 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
EP4321524B1 (en) Lipid and composition
US20260078099A1 (en) Compound, preparation method thereof, and lipid nanoparticle and pharmaceutical composition
Gosangi et al. Evolution of new “Bolaliposomes” using novel α-tocopheryl succinate based cationic lipid and 1, 12-disubstituted dodecane-based bolaamphiphile for efficient gene delivery
Neuberg et al. Design and evaluation of ionizable peptide amphiphiles for siRNA delivery
Soltan et al. Design and Synthesis of N 4, N 9-Disubstituted Spermines for Non-viral siRNA Delivery–Structure-Activity Relationship Studies of siFection Efficiency Versus Toxicity
US9822083B2 (en) Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof
Niyomtham et al. Synergistic effect of cationic lipids with different polarheads, central core structures and hydrophobic tails on gene transfection efficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150113